Analysis of Clinico-Pathological Characteristics of Indian Breast Cancers Shows Conservation of Specific Features in the Hormone Receptor Sub-TypesGeetashree Mukherjee1*, KC Lakshmaiah2, M Vijayakumar3, Jyothi S Prabhu4, Deepthi Telikicherla4, TS Sridhar4 and Rekha V Kumar1
- Corresponding Author:
- Geetashree Mukherjee
MD, Professor and Head, Kidwai Memorial Institute of Oncology
Department of Pathology, Dr. M. H. Marigowda Road
Bangalore - 560 029, Karnataka, India
E-mail: [email protected], [email protected]
Received date: January 21, 2016;Accepted date: Feburary 15, 2016; Published date: Feburary 17, 2016
Citation: Mukherjee G, Lakshmaiah KC, Vijayakumar M, Prabhu JS, Telikicherla D, et al. (2016) Analysis of Clinico-Pathological Characteristics of Indian Breast Cancers Shows Conservation of Specific Features in the Hormone Receptor Sub-Types. J Integr Oncol 5:159. doi:10.4172/2329-6771.1000159
Copyright: © 2016 Mukherjee G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Clinical epidemiology studies of breast cancer in India have reported younger age at detection, presentation at a later stage with a greater proportion of Triple Negative Breast Cancer (TNBC). The aim of this study was to examine the standard clinic-pathological variables in the hormone-receptor based sub-types for patterns indicative of intrinsic differences from that reported in Western, Caucasian women.
Methods: Clinico-pathological variables from 645 patients who were diagnosed with breast cancer during 2012 at the regional cancer were retrospectively analyzed for clinical and immunohistochemistry details.
Results: The median age at first diagnosis is 48 years which is decade earlier than that reported in Western case-series, 65% were lymph-node positive, and 33% of all cases were Triple negative Breast Cancers. Sub-type specific examination of tumor size and lymph-node (LN) status showed the HER2 positive tumors to have the highest proportion of tumors that were pT4 and 75% were LN positive. Conversely, despite 92% of TNBCs being grade 3, 40% of them were LN negative.
Conclusion: We confirm the three cardinal clinical epidemiological features reported by other Indian centres. The clinical behavior of the HER2 positive and TNBC sub-types are no different from that reported in Western caseseries suggesting that these aspects are innate and conserved.